

## **Trenchant Technologies Capital Portfolio Company GNQ Insilico Appoints Trailblazing Healthcare Visionary Dr. Maliha Hashmi to its Board of Directors Amid Major Patent Filing for Digital Twins Platform**

VANCOUVER, BC – December 10, 2024 – Trenchant Technologies Capital (CSE: AITT; OTCQB: AITTF; “**Trenchant**” or the “**Company**”) is proud to announce that its portfolio company, GNQ Insilico (“**GNQ**”), a leading health tech innovator leveraging AI and quantum computing to revolutionize healthcare, has appointed Dr. Maliha Hashmi to its Board of Directors. This milestone coincides with GNQ’s filing of its first provisional patent for its groundbreaking digital twins platform.

“Dr. Hashmi’s unparalleled distinction as a pioneer in healthcare innovation and her esteemed standing as a global health leader will bring transformative insights and exceptional leadership to our Board of Directors,” said Rehan Huda, Founder and Chief Executive Officer of GNQ Insilico.

Throughout her illustrious career, Dr. Hashmi has championed the humanization of technology, ensuring that healthcare advancements foster deeper human connections, compassion, and accessibility. Her innovative approach integrates cutting-edge smart systems designed to enhance operational efficiency, elevate patient care, and achieve groundbreaking health outcomes.

Dr. Hashmi has been widely celebrated for her contributions, including recently being ranked #1 among the Top 10 Female Innovators and Leaders Globally by Entrepreneur Mirror. She holds multiple advanced degrees from Harvard University and has served as a World Economic Forum Global Future Expert and V20 Delegate for the G20.

“I am deeply honored to join the board of GNQ Insilico,” said Dr. Hashmi. “For years, I envisioned that digital twins would play an integral role in the future of healthcare systems. GNQ’s platform has the potential to revolutionize the life sciences industry and transform healthcare delivery, and I am thrilled to contribute to this groundbreaking work.”

This appointment underscores GNQ Insilico’s commitment to driving innovation and excellence, ensuring that technological advancements continue to redefine healthcare for the better.

On December 2, 2024 GNQ Insilico filed a provisional patent on insulin dynamics optimization, a method that models relationships between insulin demand, insulin supply and efficiency. This approach uniquely combines quantum-inspired optimization (QIO) with

genetic pathway analysis and real-time adaptation, enabling personalized, dynamic treatment optimization that considers multiple biological factors simultaneously.

“We are very excited about this and the upcoming patents on a number of other conditions that we will be filing in the near future,” said Sudhir Saxena, Chief Technology Officer of GNQ Insilico. “We believe our approach is a significant advancement from conventional methods which typically only use fixed protocols or much simpler feedback mechanisms.”

**ABOUT GNQ INSILICO:**

GNQ Insilico is an AI-biotechnology company pioneering the development and application of next-generation artificial intelligence capabilities to accelerate therapeutic research, clinical development, and individualized patient care. For more information, visit [www.gnqinsilico.com](http://www.gnqinsilico.com).

**ABOUT TRENCHANT TECHNOLOGIES CAPITAL (CSE: AITT; OTCQB: AITTF; FSE: A40CR2)**

Trenchant Technologies Capital (CSE: AITT) is an investment issuer focused primarily on seeking investment in companies introducing novel technologies, including Artificial Intelligence and Quantum Computing, to traditional business models that are due for disruption.

Trenchant’s team undergoes a rigorous due diligence process to identify companies led by seasoned management teams that are strong candidates for acquisition or an initial public offering (IPO). In May 2024, Trenchant Technologies Capital acquired a 20% ownership interest in GNQ Insilico from parent company My Next Health Inc. Further, Trenchant holds an option to acquire up to 40% of GNQ.

**ON BEHALF OF THE BOARD TRENCHANT CAPITAL CORP.**

Per: “Eric Boehnke” Eric Boehnke, CEO

For further information, please contact:

Trenchant Technologies Capital Corp. Eric Boehnke, CEO

Phone: (604) 307-4274

**Forward-Looking Statements**

This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “anticipates”, “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed”, “positioned” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements, including but not limited to GNQ’s ability to successful

complete all necessary trials and regulatory approval processes necessary to be in a position to commercialize any of its technologies, including but not limited to its proprietary genomics driven platform are only predictions. Various assumptions were used in drawing the conclusions or making the predictions contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management of GNQ at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Trenchant Capital and GNQ are under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release.